Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication » 13:44
09/30/20
09/30
13:44
09/30/20
13:44
NVO

Novo Nordisk

$69.36 /

-0.845 (-1.20%)

, NVS

Novartis

$86.90 /

-0.145 (-0.17%)

, BMY

Bristol-Myers

$60.37 /

+0.48 (+0.80%)

, AKRO

Akero Therapeutics

$31.19 /

-0.1499 (-0.48%)

, ALT

Altimmune

$13.00 /

+ (+0.00%)

, ICPT

Intercept

$42.50 /

+0.75 (+1.80%)

, MIRM

Mirum Pharmaceuticals

$19.60 /

-0.1 (-0.51%)

, CBAY

CymaBay

$7.06 /

-0.02 (-0.28%)

, ETNB

89bio

$25.20 /

+0.25 (+1.00%)

, ALBO

Albireo Pharma

$33.93 /

+1.3 (+3.98%)

On Thursday, the American…

ShowHide Related Items >><<
NVO Novo Nordisk
$69.36 /

-0.845 (-1.20%)

NVS Novartis
$86.90 /

-0.145 (-0.17%)

BMY Bristol-Myers
$60.37 /

+0.48 (+0.80%)

AKRO Akero Therapeutics
$31.19 /

-0.1499 (-0.48%)

ALT Altimmune
$13.00 /

+ (+0.00%)

ICPT Intercept
$42.50 /

+0.75 (+1.80%)

MIRM Mirum Pharmaceuticals
$19.60 /

-0.1 (-0.51%)

CBAY CymaBay
$7.06 /

-0.02 (-0.28%)

ETNB 89bio
$25.20 /

+0.25 (+1.00%)

ALBO Albireo Pharma
$33.93 /

+1.3 (+3.98%)

NVO Novo Nordisk
$69.36 /

-0.845 (-1.20%)

09/29/20 Berenberg
Novo Nordisk initiated with a Hold at Berenberg
08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
NVS Novartis
$86.90 /

-0.145 (-0.17%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
BMY Bristol-Myers
$60.37 /

+0.48 (+0.80%)

09/29/20 Berenberg
Bristol-Myers initiated with a Buy at Berenberg
09/22/20 Oppenheimer
Bluebird Bio review timeline consistent with expectations, says Oppenheimer
08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
AKRO Akero Therapeutics
$31.19 /

-0.1499 (-0.48%)

09/10/20 Morgan Stanley
Akero Therapeutics initiated with an Overweight at Morgan Stanley
08/31/20 B. Riley FBR
NGM released 'overwhelmingly positive' NASH update, says B. Riley FBR
08/14/20 Piper Sandler
Piper sees 89bio's topline data beating Akero's in NASH
07/23/20 BTIG
89bio initiated with a Buy at BTIG
ALT Altimmune
$13.00 /

+ (+0.00%)

09/25/20 B. Riley FBR
Altimmune initiated with a Buy at B. Riley FBR
09/22/20 Piper Sandler
Altimmune nearing two 'key stock-moving events,' says Piper Sandler
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
08/25/20 Piper Sandler
Altimmune a 'stand out' from other COVID vaccine makers, says Piper Sandler
ICPT Intercept
$42.50 /

+0.75 (+1.80%)

09/09/20 B. Riley FBR
CymaBay price target raised to $13 from $9 at B. Riley FBR
09/02/20 Piper Sandler
Intercept workforce cut not related to potential approval, says Piper Sandler
08/28/20 Piper Sandler
Piper says Intercept data continues to tilt risk/benefit argument raised in CRL
08/27/20 Piper Sandler
Intercept's OCA 'comes out on top' at EASL, says Piper Sandler
MIRM Mirum Pharmaceuticals
$19.60 /

-0.1 (-0.51%)

09/28/20 Piper Sandler
Mirum opportunity in Alagille syndrome higher than expected, says Piper Sandler
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/01/20 Citi
Mirum Pharmaceuticals price target raised to $31 from $28 at Citi
08/07/20 Raymond James
Mirum Pharmaceuticals upgraded to Strong Buy from Outperform at Raymond James
CBAY CymaBay
$7.06 /

-0.02 (-0.28%)

09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley FBR
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
08/25/20 Citi
CymaBay price target raised to $9 from $7 at Citi
ETNB 89bio
$25.20 /

+0.25 (+1.00%)

09/25/20 BofA
89bio upgraded to Buy from Neutral at BofA
09/25/20 BofA
89bio upgraded to Buy from Neutral at BofA
09/15/20 Chardan
89bio price target raised to $95 from $59 at Chardan
09/14/20 Piper Sandler
89bio NASH data better than expected, says Piper Sandler
ALBO Albireo Pharma
$33.93 /

+1.3 (+3.98%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
NVO Novo Nordisk
$69.36 /

-0.845 (-1.20%)

NVS Novartis
$86.90 /

-0.145 (-0.17%)

BMY Bristol-Myers
$60.37 /

+0.48 (+0.80%)

AKRO Akero Therapeutics
$31.19 /

-0.1499 (-0.48%)

ICPT Intercept
$42.50 /

+0.75 (+1.80%)

MIRM Mirum Pharmaceuticals
$19.60 /

-0.1 (-0.51%)

CBAY CymaBay
$7.06 /

-0.02 (-0.28%)

ETNB 89bio
$25.20 /

+0.25 (+1.00%)

ALBO Albireo Pharma
$33.93 /

+1.3 (+3.98%)

  • 17
    Sep
  • 10
    Sep
  • 18
    Aug
  • 14
    Jul
  • 08
    Jul
  • 08
    Jul
  • 30
    Jan
  • 09
    Jan
  • 11
    Nov
NVS Novartis
$86.90 /

-0.145 (-0.17%)

BMY Bristol-Myers
$60.37 /

+0.48 (+0.80%)

NVO Novo Nordisk
$69.36 /

-0.845 (-1.20%)

NVS Novartis
$86.90 /

-0.145 (-0.17%)

BMY Bristol-Myers
$60.37 /

+0.48 (+0.80%)

AKRO Akero Therapeutics
$31.19 /

-0.1499 (-0.48%)

ALT Altimmune
$13.00 /

+ (+0.00%)

ICPT Intercept
$42.50 /

+0.75 (+1.80%)

CBAY CymaBay
$7.06 /

-0.02 (-0.28%)

ETNB 89bio
$25.20 /

+0.25 (+1.00%)

ALBO Albireo Pharma
$33.93 /

+1.3 (+3.98%)

NVO Novo Nordisk
$69.36 /

-0.845 (-1.20%)

BMY Bristol-Myers
$60.37 /

+0.48 (+0.80%)

ALT Altimmune
$13.00 /

+ (+0.00%)

CBAY CymaBay
$7.06 /

-0.02 (-0.28%)

Options
Largest borrow rate increases among liquid names » 08:45
09/30/20
09/30
08:45
09/30/20
08:45
LMND

Lemonade

$49.44 /

-1.685 (-3.30%)

, JWN

Nordstrom

$11.78 /

-0.49 (-3.99%)

, ADMA

ADMA Biologics

$2.20 /

+0.02 (+0.92%)

, SOLO

ElectraMeccanica

$2.51 /

+0.01 (+0.40%)

, IDEX

Ideanomics

$0.91 /

-0.0462 (-4.83%)

, UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$20.01 /

-0.64 (-3.10%)

, SHLL

Tortoise Acquisition

$53.49 /

+5.61 (+11.72%)

, GME

GameStop

$10.35 /

+0.28 (+2.78%)

, ALT

Altimmune

$13.01 /

+0.75 (+6.12%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Lemonade (LMND) 20.34% +4.19, Nordstrom (JWN) 5.16% +0.97, Adma Biologics (ADMA) 3.01% +0.79, Electrameccanica Vehicles Corp (SOLO) 32.80% +0.52, Ideanomics (IDEX) 80.80% +0.49, ProShares Ultra VIX Short Term Futures (UVXY) 2.11% +0.41, Tortoise Acquisition Corp (SHLL) 18.72% +0.38, GameStop (GME) 39.60% +0.35, Direxion Daily S&P Bear (SPXS) 0.98% +0.24, and Altimmune (ALT) 1.97% +0.20.

ShowHide Related Items >><<
UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$20.01 /

-0.64 (-3.10%)

SOLO ElectraMeccanica
$2.51 /

+0.01 (+0.40%)

SHLL Tortoise Acquisition
$53.49 /

+5.61 (+11.72%)

LMND Lemonade
$49.44 /

-1.685 (-3.30%)

JWN Nordstrom
$11.78 /

-0.49 (-3.99%)

IDEX Ideanomics
$0.91 /

-0.0462 (-4.83%)

GME GameStop
$10.35 /

+0.28 (+2.78%)

ALT Altimmune
$13.01 /

+0.75 (+6.12%)

ADMA ADMA Biologics
$2.20 /

+0.02 (+0.92%)

LMND Lemonade
$49.44 /

-1.685 (-3.30%)

08/14/20 Morgan Stanley
Lemonade price target lowered to $70 from $91 at Morgan Stanley
07/27/20
Fly Intel: Top five analyst initiations
07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
JWN Nordstrom
$11.78 /

-0.49 (-3.99%)

08/26/20 Citi
Nordstrom price target lowered to $17 from $19 at Citi
08/19/20 KeyBanc
Nordstrom price target lowered to $30 from $48 at KeyBanc
08/14/20 Wedbush
Wedbush cautious on Nordstrom into upcoming Q2 earnings
05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
ADMA ADMA Biologics
$2.20 /

+0.02 (+0.92%)

05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
05/07/20 Oppenheimer
ADMA Biologics price target lowered to $7 from $14 at Oppenheimer
03/16/20 H.C. Wainwright
ADMA Biologics price target lowered to $12 from $14 at H.C. Wainwright
SOLO ElectraMeccanica
$2.51 /

+0.01 (+0.40%)

04/03/20 Benchmark
ElectraMeccanica downgraded to Speculative Hold at Benchmark
IDEX Ideanomics
$0.91 /

-0.0462 (-4.83%)

UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$20.01 /

-0.64 (-3.10%)

SHLL Tortoise Acquisition
$53.49 /

+5.61 (+11.72%)

GME GameStop
$10.35 /

+0.28 (+2.78%)

09/23/20 Baird
Demand for PS5, Xbox Series X continues to look 'strong,' says Baird
09/23/20 Loop Capital
GameStop price target raised to $9 from $6 at Loop Capital
09/14/20
Fly Intel: Top five analyst upgrades
09/14/20 Jefferies
GameStop upgraded to Buy ahead of video game console cycle at Jefferies
ALT Altimmune
$13.01 /

+0.75 (+6.12%)

09/25/20 B. Riley Securities
Altimmune initiated with a Buy at B. Riley FBR
09/22/20 Piper Sandler
Altimmune nearing two 'key stock-moving events,' says Piper Sandler
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
08/25/20 Piper Sandler
Altimmune a 'stand out' from other COVID vaccine makers, says Piper Sandler
LMND Lemonade
$49.44 /

-1.685 (-3.30%)

JWN Nordstrom
$11.78 /

-0.49 (-3.99%)

GME GameStop
$10.35 /

+0.28 (+2.78%)

ADMA ADMA Biologics
$2.20 /

+0.02 (+0.92%)

  • 14
    Jul
  • 02
    Jul
  • 07
    Feb
JWN Nordstrom
$11.78 /

-0.49 (-3.99%)

IDEX Ideanomics
$0.91 /

-0.0462 (-4.83%)

GME GameStop
$10.35 /

+0.28 (+2.78%)

SHLL Tortoise Acquisition
$53.49 /

+5.61 (+11.72%)

LMND Lemonade
$49.44 /

-1.685 (-3.30%)

JWN Nordstrom
$11.78 /

-0.49 (-3.99%)

IDEX Ideanomics
$0.91 /

-0.0462 (-4.83%)

GME GameStop
$10.35 /

+0.28 (+2.78%)

ALT Altimmune
$13.01 /

+0.75 (+6.12%)

ADMA ADMA Biologics
$2.20 /

+0.02 (+0.92%)

UVXY ProShares Trust Ultra VIX Short Term Futures ETF
$20.01 /

-0.64 (-3.10%)

SOLO ElectraMeccanica
$2.51 /

+0.01 (+0.40%)

SHLL Tortoise Acquisition
$53.49 /

+5.61 (+11.72%)

LMND Lemonade
$49.44 /

-1.685 (-3.30%)

JWN Nordstrom
$11.78 /

-0.49 (-3.99%)

IDEX Ideanomics
$0.91 /

-0.0462 (-4.83%)

GME GameStop
$10.35 /

+0.28 (+2.78%)

ALT Altimmune
$13.01 /

+0.75 (+6.12%)

ADMA ADMA Biologics
$2.20 /

+0.02 (+0.92%)

Yesterday
On The Fly
Hersey, Best Buy upgrades among today's top calls on Wall Street » 10:00
09/29/20
09/29
10:00
09/29/20
10:00
HSY

Hershey

$141.40 /

+1.06 (+0.76%)

, BBY

Best Buy

$109.07 /

+0.69 (+0.64%)

, EL

Estee Lauder

$215.07 /

-0.42 (-0.19%)

, RH

RH

$371.30 /

+10.64 (+2.95%)

, BMY

Bristol-Myers

$60.19 /

+0.465 (+0.78%)

, AZN

AstraZeneca

$55.04 /

+0.33 (+0.60%)

, PFE

Pfizer

$36.38 /

-0.03 (-0.08%)

, MRK

Merck

$82.78 /

-0.02 (-0.02%)

, LLY

Eli Lilly

$148.31 /

+0.4 (+0.27%)

, ABBV

AbbVie

$86.86 /

-0.37 (-0.42%)

, NVS

Novartis

$87.81 /

+0.785 (+0.90%)

, SNY

Sanofi

$50.90 /

-0.05 (-0.10%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Check out today's top…

ShowHide Related Items >><<
SNY Sanofi
$50.90 /

-0.05 (-0.10%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RH RH
$371.30 /

+10.64 (+2.95%)

PFE Pfizer
$36.38 /

-0.03 (-0.08%)

NVS Novartis
$87.81 /

+0.785 (+0.90%)

MRK Merck
$82.78 /

-0.02 (-0.02%)

LLY Eli Lilly
$148.31 /

+0.4 (+0.27%)

HSY Hershey
$141.40 /

+1.06 (+0.76%)

EL Estee Lauder
$215.07 /

-0.42 (-0.19%)

BMY Bristol-Myers
$60.19 /

+0.465 (+0.78%)

BBY Best Buy
$109.07 /

+0.69 (+0.64%)

AZN AstraZeneca
$55.04 /

+0.33 (+0.60%)

ABBV AbbVie
$86.86 /

-0.37 (-0.42%)

HSY Hershey
$141.40 /

+1.06 (+0.76%)

09/29/20
Fly Intel: Top five analyst upgrades
09/29/20 BMO Capital
Hershey upgraded to Outperform from Market Perform at BMO Capital
07/24/20 Evercore ISI
Hershey upgraded to Outperform from In Line at Evercore ISI
04/24/20
Fly Intel: Top five analyst downgrades
BBY Best Buy
$109.07 /

+0.69 (+0.64%)

09/29/20 Cleveland Research
Best Buy upgraded to Buy from Neutral at Cleveland Research
09/29/20 Cleveland Research
Best Buy upgraded to Buy from Neutral at Cleveland Research
09/01/20 Loop Capital
Best Buy pricing narrows relative to Amazon.com, says Loop Capital
08/27/20 DA Davidson
Dick's Sporting price target raised to $67 from $57 at DA Davidson
EL Estee Lauder
$215.07 /

-0.42 (-0.19%)

09/28/20 Goldman Sachs
Estee Lauder upgraded to Neutral from Sell at Goldman Sachs
09/04/20 Raymond James
Estee Lauder price target raised to $235 from $210 at Raymond James
09/03/20 Morgan Stanley
Brown-Forman price target raised to $66 from $56 at Morgan Stanley
08/26/20 Argus
Estee Lauder price target raised to $240 from $220 at Argus
RH RH
$371.30 /

+10.64 (+2.95%)

09/29/20 Cowen
Cowen upgrades RH to Outperform with transformation in 'earlier innings'
09/29/20 Cowen
RH upgraded to Outperform from Market Perform at Cowen
09/10/20 JPMorgan
RH price target raised to $440 from $370 at JPMorgan
BMY Bristol-Myers
$60.19 /

+0.465 (+0.78%)

09/29/20 Berenberg
Bristol-Myers initiated with a Buy at Berenberg
09/22/20 Oppenheimer
Bluebird Bio review timeline consistent with expectations, says Oppenheimer
08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
AZN AstraZeneca
$55.04 /

+0.33 (+0.60%)

09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
09/28/20 Maxim
Maxim upgrades Inovio to Buy, says shares oversold after vaccine 'speed bump'
09/23/20 Oddo BHF
AstraZeneca upgraded to Buy from Reduce at Oddo BHF
09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
PFE Pfizer
$36.38 /

-0.03 (-0.08%)

09/29/20
Fly Intel: Top five analyst initiations
09/29/20 Berenberg
Pfizer initiated with a Hold at Berenberg
09/21/20 Morgan Stanley
Eli Lilly's Verzenio 'clear winner' over Pfizer's Ibrance, says Morgan Stanley
09/16/20 Baird
uniQure weakness a buying opportunity, says Baird
MRK Merck
$82.78 /

-0.02 (-0.02%)

09/29/20 Berenberg
Merck initiated with a Hold at Berenberg
09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
LLY Eli Lilly
$148.31 /

+0.4 (+0.27%)

09/29/20 Berenberg
Eli Lilly initiated with a Hold at Berenberg
09/16/20 Canaccord
Eli Lilly COVID-19 data bodes well for Regeneron, says Canaccord
09/16/20 Goldman Sachs
Eli Lilly COVID-19 antibody data 'encouraging,' says Goldman Sachs
ABBV AbbVie
$86.86 /

-0.37 (-0.42%)

09/29/20 Berenberg
AbbVie initiated with a Hold at Berenberg
09/28/20 Mizuho
Mizuho 'incrementally more bullish' on AbbVie integration of Allergan
09/02/20 Citi
AbbVie revenue potential offsets subpoena risk, says Citi
08/24/20 H.C. Wainwright
Galapagos downgraded to Neutral from Buy at H.C. Wainwright
NVS Novartis
$87.81 /

+0.785 (+0.90%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
SNY Sanofi
$50.90 /

-0.05 (-0.10%)

09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/14/20 Roth Capital
Immunic has 'significant' opportunity in RRMS, says Roth Capital
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
RHHBY Roche
$0.00 /

+ (+0.00%)

09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
09/28/20 Societe Generale
Roche price target raised to CHF 420 from CHF 365 at Societe Generale
09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
SNY Sanofi
$50.90 /

-0.05 (-0.10%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RH RH
$371.30 /

+10.64 (+2.95%)

PFE Pfizer
$36.38 /

-0.03 (-0.08%)

NVS Novartis
$87.81 /

+0.785 (+0.90%)

MRK Merck
$82.78 /

-0.02 (-0.02%)

LLY Eli Lilly
$148.31 /

+0.4 (+0.27%)

HSY Hershey
$141.40 /

+1.06 (+0.76%)

EL Estee Lauder
$215.07 /

-0.42 (-0.19%)

BMY Bristol-Myers
$60.19 /

+0.465 (+0.78%)

BBY Best Buy
$109.07 /

+0.69 (+0.64%)

AZN AstraZeneca
$55.04 /

+0.33 (+0.60%)

ABBV AbbVie
$86.86 /

-0.37 (-0.42%)

SNY Sanofi
$50.90 /

-0.05 (-0.10%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RH RH
$371.30 /

+10.64 (+2.95%)

PFE Pfizer
$36.38 /

-0.03 (-0.08%)

NVS Novartis
$87.81 /

+0.785 (+0.90%)

MRK Merck
$82.78 /

-0.02 (-0.02%)

LLY Eli Lilly
$148.31 /

+0.4 (+0.27%)

HSY Hershey
$141.40 /

+1.06 (+0.76%)

EL Estee Lauder
$215.07 /

-0.42 (-0.19%)

BMY Bristol-Myers
$60.19 /

+0.465 (+0.78%)

BBY Best Buy
$109.07 /

+0.69 (+0.64%)

AZN AstraZeneca
$55.04 /

+0.33 (+0.60%)

SNY Sanofi
$50.90 /

-0.05 (-0.10%)

RH RH
$371.30 /

+10.64 (+2.95%)

PFE Pfizer
$36.38 /

-0.03 (-0.08%)

NVS Novartis
$87.81 /

+0.785 (+0.90%)

MRK Merck
$82.78 /

-0.02 (-0.02%)

LLY Eli Lilly
$148.31 /

+0.4 (+0.27%)

HSY Hershey
$141.40 /

+1.06 (+0.76%)

EL Estee Lauder
$215.07 /

-0.42 (-0.19%)

BMY Bristol-Myers
$60.19 /

+0.465 (+0.78%)

BBY Best Buy
$109.07 /

+0.69 (+0.64%)

AZN AstraZeneca
$55.04 /

+0.33 (+0.60%)

ABBV AbbVie
$86.86 /

-0.37 (-0.42%)

SNY Sanofi
$50.90 /

-0.05 (-0.10%)

RH RH
$371.30 /

+10.64 (+2.95%)

PFE Pfizer
$36.38 /

-0.03 (-0.08%)

MRK Merck
$82.78 /

-0.02 (-0.02%)

LLY Eli Lilly
$148.31 /

+0.4 (+0.27%)

EL Estee Lauder
$215.07 /

-0.42 (-0.19%)

BMY Bristol-Myers
$60.19 /

+0.465 (+0.78%)

BBY Best Buy
$109.07 /

+0.69 (+0.64%)

AZN AstraZeneca
$55.04 /

+0.33 (+0.60%)

ABBV AbbVie
$86.86 /

-0.37 (-0.42%)

Initiation
Merck initiated with a Hold at Berenberg » 05:28
09/29/20
09/29
05:28
09/29/20
05:28
MRK

Merck

$82.80 /

-0.15 (-0.18%)

Berenberg analyst Luisa…

Berenberg analyst Luisa Hector initiated coverage of Merck with a Hold rating and $88 price target. The analyst sees solid fundamentals and attractive valuations in the global pharma space. Hector forecasts 6% annual sales growth and a 10% earnings compound annual growth rate for the sector through 2024.

ShowHide Related Items >><<
MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

Hot Stocks
Celyad, Merck enter collaboration to evaluate CYAD-101 with Keytruda » 05:14
09/29/20
09/29
05:14
09/29/20
05:14
CYAD

Celyad

$9.16 /

+ (+0.00%)

, MRK

Merck

$82.80 /

-0.15 (-0.18%)

Celyad (CYAD) announced…

Celyad (CYAD) announced that the company has entered into a clinical trial collaboration with Merck (MRK), through a subsidiary. Celyad Oncology will conduct the Phase 1b KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncology's investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI preconditioning chemotherapy, with Merck's anti-PD-1 therapy, Keytruda in refractory metastatic colorectal cancer, or mCRC, patients with microsatellite stable / mismatch-repair proficient disease.

ShowHide Related Items >><<
MRK Merck
$82.80 /

-0.15 (-0.18%)

CYAD Celyad
$9.16 /

+ (+0.00%)

CYAD Celyad
$9.16 /

+ (+0.00%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
MRK Merck
$82.80 /

-0.15 (-0.18%)

09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

MRK Merck
$82.80 /

-0.15 (-0.18%)

Friday
On The Fly
Fly Intel: Pre-market Movers » 09:08
09/25/20
09/25
09:08
09/25/20
09:08
APO

Apollo Global

$42.86 /

-1.125 (-2.56%)

, WIMHY

William Hill

$0.00 /

+ (+0.00%)

, NVAX

Novavax

$102.48 /

+0.92 (+0.91%)

, DKNG

DraftKings

$50.58 /

+0.48 (+0.96%)

, CLNY

Colony Capital

$2.34 /

-0.03 (-1.27%)

, OUT

Outfront Media

$14.00 /

-0.16 (-1.13%)

, ALT

Altimmune

$12.03 /

-0.5 (-3.99%)

, COST

Costco

$347.25 /

+2.67 (+0.77%)

, FLR

Fluor

$9.35 /

+0.865 (+10.19%)

, NETE

Net Element

$8.60 /

+2.16 (+33.54%)

, ENDP

Endo

$3.03 /

-0.035 (-1.14%)

Check out this morning's…

ShowHide Related Items >><<
WIMHY William Hill
$0.00 /

+ (+0.00%)

OUT Outfront Media
$14.00 /

-0.16 (-1.13%)

NVAX Novavax
$102.48 /

+0.92 (+0.91%)

NETE Net Element
$8.60 /

+2.16 (+33.54%)

FLR Fluor
$9.35 /

+0.865 (+10.19%)

ENDP Endo
$3.03 /

-0.035 (-1.14%)

DKNG DraftKings
$50.58 /

+0.48 (+0.96%)

COST Costco
$347.25 /

+2.67 (+0.77%)

CLNY Colony Capital
$2.34 /

-0.03 (-1.27%)

APO Apollo Global
$42.86 /

-1.125 (-2.56%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

APO Apollo Global
$42.86 /

-1.125 (-2.56%)

07/01/20 Barclays
Apollo Global price target raised to $51 from $44 at Barclays
06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Goldman Sachs
Apollo Global downgraded to Buy from Conviction Buy at Goldman Sachs
06/08/20 Citi
Citi downgrades Alternative Asset Managers to Market Weight, lowers four ratings
WIMHY William Hill
$0.00 /

+ (+0.00%)

09/14/20 Jefferies
William Hill shares haven't priced in building U.S. momentum, says Jefferies
09/10/20 Berenberg
William Hill price target raised to 200 GBp from 150 GBp at Berenberg
09/09/20 Morgan Stanley
William Hill price target raised to 230 GBp from 200 GBp at Morgan Stanley
09/08/20 Barclays
William Hill price target raised to 240 GBp from 200 GBp at Barclays
NVAX Novavax
$102.48 /

+0.92 (+0.91%)

09/15/20 B. Riley Securities
Novavax deal with SIIPL doubles manufacturing capacity, says B. Riley FBR
09/09/20 B. Riley Securities
Astra trial hold opens window for other vaccine candidates, says B. Riley FBR
09/08/20 B. Riley Securities
Novavax selloff brings 'compelling' buying opportunity, says B. Riley FBR
09/03/20 Cantor Fitzgerald
Cantor says Novavax publication in NEJM gives 'validation' for vaccine candidate
DKNG DraftKings
$50.58 /

+0.48 (+0.96%)

09/25/20 Argus
DraftKings initiated with a Buy at Argus
09/25/20 Argus
DraftKings initiated with a Buy at Argus
09/24/20
Fly Intel: Top five analyst initiations
09/24/20 Macquarie
DraftKings initiated with an Outperform at Macquarie
CLNY Colony Capital
$2.34 /

-0.03 (-1.27%)

06/04/20 B. Riley Securities
Colony Capital price target lowered to $4 from $5 at B. Riley FBR
03/11/20 B. Riley Securities
B. Riley FBR downgrades CNO Financial, Progressive to Neutral from Buy
OUT Outfront Media
$14.00 /

-0.16 (-1.13%)

09/25/20 Citi
Outfront Media upgraded to Buy from Neutral at Citi
06/24/20 Citi
Clear Channel Outdoor upgraded to Buy from Neutral at Citi
04/22/20 Imperial Capital
Outfront Media price target lowered to $22 from $24 at Imperial Capital
04/20/20 Morgan Stanley
Morgan Stanley downgrades Outfront Media, slashes price target to $13
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

09/25/20 B. Riley Securities
Altimmune initiated with a Buy at B. Riley FBR
09/22/20 Piper Sandler
Altimmune nearing two 'key stock-moving events,' says Piper Sandler
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
08/25/20 Piper Sandler
Altimmune a 'stand out' from other COVID vaccine makers, says Piper Sandler
COST Costco
$347.25 /

+2.67 (+0.77%)

09/25/20 BMO Capital
Costco price target raised to $385 from $340 at BMO Capital
09/25/20 Raymond James
Costco price target raised to $365 from $355 at Raymond James
09/25/20 Morgan Stanley
Costco price target raised to $360 from $330 at Morgan Stanley
09/25/20 Baird
Costco chances of special dividend rising, says Baird
FLR Fluor
$9.35 /

+0.865 (+10.19%)

04/27/20 Citi
Fluor downgraded to Neutral from Buy at Citi
04/27/20 UBS
Fluor downgraded to Neutral from Buy at UBS
02/19/20
Fly Intel: Top five analyst downgrades
02/19/20 DA Davidson
Fluor price target lowered to $15 from $22 at DA Davidson
NETE Net Element
$8.60 /

+2.16 (+33.54%)

ENDP Endo
$3.03 /

-0.035 (-1.14%)

07/27/20 Goldman Sachs
Endo initiated with a Sell at Goldman Sachs
06/17/20 Citi
Sell Mallinckrodt, buy Endo with opioid risk coming back, says Citi
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Endo initiated with a Buy at Citi
OUT Outfront Media
$14.00 /

-0.16 (-1.13%)

NVAX Novavax
$102.48 /

+0.92 (+0.91%)

FLR Fluor
$9.35 /

+0.865 (+10.19%)

ENDP Endo
$3.03 /

-0.035 (-1.14%)

DKNG DraftKings
$50.58 /

+0.48 (+0.96%)

COST Costco
$347.25 /

+2.67 (+0.77%)

CLNY Colony Capital
$2.34 /

-0.03 (-1.27%)

APO Apollo Global
$42.86 /

-1.125 (-2.56%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

  • 14
    Jul
  • 19
    Jun
  • 26
    Nov
WIMHY William Hill
$0.00 /

+ (+0.00%)

NVAX Novavax
$102.48 /

+0.92 (+0.91%)

FLR Fluor
$9.35 /

+0.865 (+10.19%)

DKNG DraftKings
$50.58 /

+0.48 (+0.96%)

COST Costco
$347.25 /

+2.67 (+0.77%)

CLNY Colony Capital
$2.34 /

-0.03 (-1.27%)

APO Apollo Global
$42.86 /

-1.125 (-2.56%)

NVAX Novavax
$102.48 /

+0.92 (+0.91%)

FLR Fluor
$9.35 /

+0.865 (+10.19%)

ENDP Endo
$3.03 /

-0.035 (-1.14%)

DKNG DraftKings
$50.58 /

+0.48 (+0.96%)

COST Costco
$347.25 /

+2.67 (+0.77%)

APO Apollo Global
$42.86 /

-1.125 (-2.56%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

NVAX Novavax
$102.48 /

+0.92 (+0.91%)

FLR Fluor
$9.35 /

+0.865 (+10.19%)

ENDP Endo
$3.03 /

-0.035 (-1.14%)

DKNG DraftKings
$50.58 /

+0.48 (+0.96%)

COST Costco
$347.25 /

+2.67 (+0.77%)

APO Apollo Global
$42.86 /

-1.125 (-2.56%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

Initiation
Altimmune initiated with a Buy at B. Riley FBR » 08:59
09/25/20
09/25
08:59
09/25/20
08:59
ALT

Altimmune

$12.03 /

-0.5 (-3.99%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani initiated coverage of Altimmune with a Buy rating and $31 price target. The company's single-dose, intranasal AdCOVID could emerge as a leader in second wave of Covid-19 vaccine candidates, Mamtani tells investors in a research note. Altimmune also has a differentiated approach in nonalcoholic steatohepatitis that addresses weight loss and liver fat reduction, adds the analyst. Mamtani recommends owning the stock into "key de-risking" first-in-human datasets anticipated in the first half of 2021.

ShowHide Related Items >><<
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

09/22/20 Piper Sandler
Altimmune nearing two 'key stock-moving events,' says Piper Sandler
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
08/25/20 Piper Sandler
Altimmune a 'stand out' from other COVID vaccine makers, says Piper Sandler
08/25/20 JMP Securities
Altimmune's AdCOVID to have 'unique advantages' over other vaccines, says JMP
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

  • 14
    Jul
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

Conference/Events
European Association for the Study of Diabetes to hold a virtual annual meeting » 05:55
09/25/20
09/25
05:55
09/25/20
05:55
ABT

Abbott

$100.91 /

-1.81 (-1.76%)

, AMRN

Amarin

$3.64 /

-0.035 (-0.95%)

, AMYT

Amryt Pharma

$11.57 /

-0.48 (-3.98%)

, AZN

AstraZeneca

$54.18 /

-1.495 (-2.69%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, DXCM

DexCom

$382.64 /

-2.39 (-0.62%)

, GILD

Gilead

$62.26 /

-0.85 (-1.35%)

, LLY

Eli Lilly

$148.89 /

-1 (-0.67%)

, MDT

Medtronic

$101.30 /

-0.52 (-0.51%)

, MRK

Merck

$83.17 /

+0.54 (+0.65%)

, NVO

Novo Nordisk

$68.25 /

-1.195 (-1.72%)

, NVS

Novartis

$86.30 /

-1.15 (-1.32%)

, PODD

Insulet

$216.60 /

-11.07 (-4.86%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, SNY

Sanofi

$50.75 /

+0.15 (+0.30%)

, TNDM

TNDM

/

+

, VTVT

vTv Therapeutics

$1.73 /

-0.09 (-4.95%)

56th Virtual Annual…

56th Virtual Annual Meeting of EASD will be held on September 21-25. Webcast Link

ShowHide Related Items >><<
VTVT vTv Therapeutics
$1.73 /

-0.09 (-4.95%)

TNDM TNDM
/

+

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PODD Insulet
$216.60 /

-11.07 (-4.86%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMYT Amryt Pharma
$11.57 /

-0.48 (-3.98%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

09/11/20 Wolfe Research
Abbott initiated with an Outperform at Wolfe Research
08/31/20 Credit Suisse
Abbott price target raised to $136 from $109 at Credit Suisse
08/28/20 Canaccord
Hospital service channel shares weakness a buying opportunity, says Canaccord
08/28/20 Piper Sandler
COVID-19 test provider selloff on Abbott approval overdone, says Piper
AMRN Amarin
$3.64 /

-0.035 (-0.95%)

09/08/20 Cantor Fitzgerald
Amarin price target lowered to $15 from $35 at Cantor Fitzgerald
09/04/20 Northland
Amarin generic competitors to be constrained by supply chains, says Northland
09/04/20 Goldman Sachs
Goldman sees Amarin investor focus shifting to 'significant' Europe opportunity
09/03/20 Stifel
Amarin price target lowered to $5 from $8 at Stifel
AMYT Amryt Pharma
$11.57 /

-0.48 (-3.98%)

07/20/20
Fly Intel: Top five analyst initiations
07/20/20 Canaccord
Amryt Pharma initiated with a Buy at Canaccord
07/09/20
Fly Intel: Top five analyst initiations
07/08/20 Cantor Fitzgerald
Cantor Fitzgerald starts Amryt at Overweight, sees number of catalysts upcoming
AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

09/23/20 Oddo BHF
AstraZeneca upgraded to Buy from Reduce at Oddo BHF
09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
BAYRY Bayer
$0.00 /

+ (+0.00%)

09/14/20 Morgan Stanley
Bayer price target lowered to EUR 82 from EUR 83 at Morgan Stanley
09/10/20
Fly Intel: Top five analyst initiations
09/10/20 Roth Capital
Dare Bioscience resumed with a Buy at Roth Capital
09/09/20 BMO Capital
Bayer initiated with a Market Perform at BMO Capital
DXCM DexCom
$382.64 /

-2.39 (-0.62%)

08/11/20 Piper Sandler
Medtronic acquisition of Companion 'a smart decision,' says Piper Sandler
07/29/20 SVB Leerink
DexCom price target raised to $485 from $465 at SVB Leerink
07/29/20 Guggenheim
DexCom price target raised to $500 from $395 at Guggenheim
07/29/20 Canaccord
DexCom price target raised to $500 from $435 at Canaccord
GILD Gilead
$62.26 /

-0.85 (-1.35%)

09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
LLY Eli Lilly
$148.89 /

-1 (-0.67%)

09/21/20 Morgan Stanley
Eli Lilly's Verzenio 'clear winner' over Pfizer's Ibrance, says Morgan Stanley
09/16/20 Canaccord
Eli Lilly COVID-19 data bodes well for Regeneron, says Canaccord
09/16/20 Goldman Sachs
Eli Lilly COVID-19 antibody data 'encouraging,' says Goldman Sachs
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
MDT Medtronic
$101.30 /

-0.52 (-0.51%)

09/11/20 Wolfe Research
Medtronic initiated with a Peer Perform at Wolfe Research
08/26/20 Raymond James
Medtronic price target raised to $115 from $107 at Raymond James
08/26/20 BTIG
Medtronic price target raised to $111 from $102 at BTIG
08/26/20 Citi
Medtronic price target raised to $120 from $108 at Citi
MRK Merck
$83.17 /

+0.54 (+0.65%)

09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

08/18/20 UBS
Novo Nordisk price target lowered to DKK 415 from DKK 425 at UBS
08/03/20 Morgan Stanley
Novo Nordisk price target lowered to DKK 425 from DKK 435 at Morgan Stanley
07/06/20 BofA
Novo Nordisk downgraded to Neutral from Buy at BofA
06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
NVS Novartis
$86.30 /

-1.15 (-1.32%)

09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
09/23/20 Oddo BHF
Novartis downgraded to Neutral from Buy at Oddo BHF
PODD Insulet
$216.60 /

-11.07 (-4.86%)

08/07/20 Stephens
Insulet price target raised to $230 from $165 at Stephens
08/07/20 Citi
Insulet price target raised to $255 from $200 at Citi
08/06/20 Piper Sandler
Insulet price target raised to $260 from $235 at Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

09/23/20 BMO Capital
Blueprint Medicines price target raised to $113 from $105 at BMO Capital
09/23/20 Oddo BHF
Roche downgraded to Reduce from Buy at Oddo BHF
09/21/20 H.C. Wainwright
Turning Point price target raised to $100 from $88 at H.C. Wainwright
SNY Sanofi
$50.75 /

+0.15 (+0.30%)

09/14/20 Roth Capital
Immunic has 'significant' opportunity in RRMS, says Roth Capital
08/24/20 SVB Leerink
SVB Leerink continues to view Alexion as good M&A fit for number of suitors
08/19/20 Stifel
Principia Biopharma downgraded to Hold from Buy at Stifel
TNDM TNDM
/

+

08/20/20
Fly Intel: Top five analyst initiationsNewPage
08/20/20 Wells Fargo
Tandem Diabetes initiated with an Overweight at Wells Fargo
07/31/20 Craig-Hallum
Tandem Diabetes price target raised to $140 from $102 at Craig-Hallum
VTVT vTv Therapeutics
$1.73 /

-0.09 (-4.95%)

02/10/20 H.C. Wainwright
vTv Therapeutics price target raised to $6 from $5 at H.C. Wainwright
TNDM TNDM
/

+

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PODD Insulet
$216.60 /

-11.07 (-4.86%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

  • 13
    May
SNY Sanofi
$50.75 /

+0.15 (+0.30%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

TNDM TNDM
/

+

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

PODD Insulet
$216.60 /

-11.07 (-4.86%)

NVS Novartis
$86.30 /

-1.15 (-1.32%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

DXCM DexCom
$382.64 /

-2.39 (-0.62%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

SNY Sanofi
$50.75 /

+0.15 (+0.30%)

NVO Novo Nordisk
$68.25 /

-1.195 (-1.72%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MDT Medtronic
$101.30 /

-0.52 (-0.51%)

LLY Eli Lilly
$148.89 /

-1 (-0.67%)

GILD Gilead
$62.26 /

-0.85 (-1.35%)

AZN AstraZeneca
$54.18 /

-1.495 (-2.69%)

AMRN Amarin
$3.64 /

-0.035 (-0.95%)

ABT Abbott
$100.91 /

-1.81 (-1.76%)

Hot Stocks
Ipsen appoints Philippe Lopes-Fernandes as chief business officer » 05:10
09/25/20
09/25
05:10
09/25/20
05:10
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

, MRK

Merck

$83.17 /

+0.54 (+0.65%)

Ipsen (IPSEY) announced…

Ipsen (IPSEY) announced the appointment of Philippe Lopes-Fernandes as executive VP, chief business officer, effective October 1. Based in Cambridge, Massachusetts, he will be responsible for business development and alliance management, reporting directly to David Loew, CEO, Ipsen. Lopes-Fernandes will serve on the executive leadership team. Prior to joining Ipsen, Philippe worked at Merck (MRK) where he was the senior VP, global head of business development and alliance management, based in Cambridge.

ShowHide Related Items >><<
MRK Merck
$83.17 /

+0.54 (+0.65%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/21/20 Kepler Cheuvreux
Ipsen downgraded to Reduce from Hold at Kepler Cheuvreux
09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
MRK Merck
$83.17 /

+0.54 (+0.65%)

09/24/20 Roth Capital
Merck data suggests 'another shot on goal' for Jounce, says Roth Capital
09/22/20 Stifel
Seattle Genetics price target raised to $165 from $145 at Stifel
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
MRK Merck
$83.17 /

+0.54 (+0.65%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

MRK Merck
$83.17 /

+0.54 (+0.65%)

Conference/Events
Altimmune participates in a conference call hosted by JMP Securities » 04:55
09/25/20
09/25
04:55
09/25/20
04:55
ALT

Altimmune

$12.03 /

-0.5 (-3.99%)

Conference call with…

Conference call with management will be held on September 25 hosted by JMP Securities.

ShowHide Related Items >><<
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

09/22/20 Piper Sandler
Altimmune nearing two 'key stock-moving events,' says Piper Sandler
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
08/25/20 Piper Sandler
Altimmune a 'stand out' from other COVID vaccine makers, says Piper Sandler
08/25/20 JMP Securities
Altimmune's AdCOVID to have 'unique advantages' over other vaccines, says JMP
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

  • 14
    Jul
ALT Altimmune
$12.03 /

-0.5 (-3.99%)

ALT Altimmune
$12.03 /

-0.5 (-3.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.